Causality Assessment

Causality Assessment

  1. lut 28, 2025

What Does 'Causality Assessment’ Mean?

Causality assessment is the process of evaluating the relationship between an adverse event and a drug or medical intervention. It involves determining whether there is a reasonable possibility that the drug or intervention caused or contributed to the observed adverse event.

This assessment is a critical component of pharmacovigilance and clinical research, helping to identify potential safety issues with medications or treatments. Causality assessment typically considers factors such as temporal relationship, biological plausibility, dose-response relationship, and the presence of alternative explanations.

Why Is the 'Causality Assessment’ Important in Clinical Research?

Causality assessment is crucial in clinical research as it helps ensure patient safety and the integrity of study results. By systematically evaluating the relationship between interventions and adverse events, researchers can identify potential risks associated with new treatments and make informed decisions about their safety profiles.

Furthermore, causality assessment plays a vital role in regulatory processes and post-marketing surveillance. It aids in the development of accurate drug labeling, supports decision-making for regulatory authorities, and contributes to the ongoing monitoring of drug safety in real-world settings.

Good Practices and Procedures

  1. Implement standardized causality assessment tools such as the Naranjo algorithm or WHO-UMC criteria to ensure consistency across evaluations
  2. Conduct blinded reviews by multiple independent experts to minimize bias in assessments
  3. Incorporate dechallenge and rechallenge data when available to strengthen causal inferences
  4. Regularly update causality assessments as new information becomes available throughout the study or post-marketing period
  5. Document all reasoning and evidence considered in the assessment process for transparency and future reference

Related Terms

Read more

How clinical trials can become a strategic asset for biotech startups

Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…

Advancing PET Innovation at SNMMI 2025

Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…